Why Is Exact Sciences Stock Trading Higher On Monday?

On Monday, the Centers for Medicare & Medicaid Services posted final payment determinations for its 2025 Clinical Laboratory Fee Schedule.Included was a final decision related to CMS pricing for Exact Sciences Corp’s EXAS Cologuard Plus, a second-generation test that received FDA approval in October.William Blair writes that the determinations effectively raise reimbursement by 16% versus the current Medicare rate for the first-generation Cologuard test (to $592 for Cologuard Plus from $509 for Cologuard).A ...